EpiPen Direct Buyers, Mylan Get Final OK On Antitrust Deal

By Jared Foretek · May 22, 2025, 6:53 PM EDT

Mylan Pharmaceuticals' $73.5 million settlement with a class of direct EpiPen buyers has received final approval from a Kansas federal judge, closing out claims from institutional drug resellers that Mylan worked...

To view the full article, register now.

Documents

Case Information

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020